Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Alpha Cognition Inc ACOGF


Primary Symbol: C.ACOG

Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS.


CSE:ACOG - Post by User

Post by StockHawk1on Dec 02, 2021 4:48pm
110 Views
Post# 34192168

Internal news for $ACOG.V (new CMO)

Internal news for $ACOG.V (new CMO)

Big internal news for Alpha Cognition ( $ACOG.V/$ACOGF )


The biopharmaceutical company announced today that they have appointed Dr.Cedric O’Gorman (M.D.) as their Chief Medical Officer. 


O'Gorman will support $ACOG's clinical-stage ALPHA-1062 & ALPHA-0602 drugs by leading medical, clinical and regulatory functions and he will serve as a member of the executive management team.


O’Gorman's past experience includes

- Senior Vice President at Clinical Development and Medical Affairs at Axsome Therapeutics 

- Vice President of Medical Affairs at Intra-Cellular Therapies

- U.S. Medical Lead for Psychiatry at Genentech/Roche. 

- Representing medical affairs on several branded neuroscience products for schizophrenia, bipolar disorder, and major depressive disorder at Pfizer


Overall I think this is a really good new hire and will bode well for $ACOG


More info here: 

https://finance.yahoo.com/news/alpha-cognition-appoints-cedric-o-140000680.html


$ACOG @ $1.10/share


MC $67.646M

 
<< Previous
Bullboard Posts
Next >>